- About Us
-
Our Business
-
- Therapeutic Areas Our portfolio is diverse and based upon - Market Research, Regulatory & IP.
- Licensing Licensing activities are excellent opportunities for companies to expand their portfolio.
- Biosimilar Biosimilar are biologic medicines that are developed to match their reference medicine.
-
- CRAM India has grown to be one of the key nations complying GMP manufacturing norms.
- Medical Devices REVA help our clients to deliver customized, cost-effective medical device value chain.
-
API
-
Dosage form
-
-
Operations
- At Reva, we have requisite infrastructure, with a balanced reach across Regulated, Emerging & Expansion markets. And we are committed to helping create healthier communities worldwide through education, outreach and better access to treatment.
-
Research & Development
-
Manufacturing
-
Quality
- Media
- Contact us
REVA PHARMA "Participation" at the 34th ANNUAL AAPI CONVENTION "New York" USA | 03 July, 2016
Reva Pharma was represented by Dr Sandhu at the 34th Annual AAPI Convention at New York. The AAPI (American Association of Physicians of Indian Origin) is the largest professional body in the U.S. The association (AAPI) represents the interest of more than one hundred thousand physicians of Indian origin based in the United States and one in every seven persons in the United States is touched by a physician of Indian origin.
Dr Sandhu interacted with the President AAPI (Dr Seema Jain) and her team and participated at the Healthcare CEO Forum "HealthCare 2020 & Beyond". The event was attended by personalities from Medical & Pharmaceuticals companies, U.S. Legislators, Diplomats and Healthcare NGO's.
Lecture was delivered by Dr Sandhu on subject: "INDIA’S RACE TOWARDS – GENERIC MEDICINE" on 3rd July at the main event of AAPI forum. The growth trends of generic medicine and India's growing dominance in the sector were outlined in the talk.